---
title: "Bayer Aktiengesellschaft (BAYRY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BAYRY.US.md"
symbol: "BAYRY.US"
name: "Bayer Aktiengesellschaft"
industry: "Pharmaceuticals"
datetime: "2026-05-01T01:18:55.263Z"
locales:
  - [en](https://longbridge.com/en/quote/BAYRY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BAYRY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BAYRY.US.md)
---

# Bayer Aktiengesellschaft (BAYRY.US)

## Company Overview

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.bayer.com](https://www.bayer.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-30T04:30:18.000Z

**Overall: D (0.65)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 125 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.72% |  |
| Net Profit YoY | -51.90% |  |
| P/B Ratio | 1.36 |  |
| Dividend Ratio | 0.31% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 41418999297.12 |  |
| Revenue | 52512224256.84 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -12.51% | D |
| Profit Margin | -7.94% | D |
| Gross Margin | 59.35% | A |
| Revenue YoY | 4.72% | C |
| Net Profit YoY | -51.90% | D |
| Total Assets YoY | 6.49% | B |
| Net Assets YoY | -8.16% | D |
| Cash Flow Margin | -163.81% | E |
| OCF YoY | 4.72% | C |
| Turnover | 0.42 | C |
| Gearing Ratio | 75.07% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Bayer Aktiengesellschaft",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.72%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-51.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.36",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.31%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "41418999297.12",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "52512224256.84",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-12.51%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-7.94%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "59.35%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "4.72%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-51.90%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.49%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-8.16%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-163.81%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "4.72%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "75.07%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.93 | 187/188 | - | - | - |
| PB | 1.36 | 67/188 | 1.42 | 0.91 | 0.86 |
| PS (TTM) | 0.79 | 27/188 | 0.86 | 0.64 | 0.60 |
| Dividend Yield | 0.31% | 35/188 | 0.41% | 0.37% | 0.28% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 05 | Novo Nordisk AS (NVO.US) | A | B | B | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-15T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 25% |
| Overweight | 2 | 50% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.17 |
| Highest Target | 15.30 |
| Lowest Target | 11.70 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BAYRY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BAYRY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BAYRY.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**